Guideline
SAJHIVMED DECEMBER 2013, Vol. 14, No. 4
Handout presentations in PDF for illustrating lectures
Accessed May 2014
Mood disorders
Chapter E.2
2018
9th Edition
Offering information on HIV/AIDS treatment, prevention, and research
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
New England Journal of Medicine
April 9, 2021
DOI: 10.1056/NEJMoa2104840
7 April 2021
Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed.
Available in Englisch, French and Russian
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
Orientations provisoires 19 juillet 2021
interim guidance, 19 July 2021 (arabic version)
updated version: 04/10/2021
Information about vaccine administration